|
SORL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.39220002193241E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.97580000027564E-07 |
| Normal-vs-Stage2 |
7.257800E-03 |
| Normal-vs-Stage3 |
6.01800054234047E-10 |
| Normal-vs-Stage4 |
3.42849999945827E-07 |
| Stage1-vs-Stage2 |
9.035000E-01 |
| Stage1-vs-Stage3 |
9.005700E-02 |
| Stage1-vs-Stage4 |
4.555400E-01 |
| Stage2-vs-Stage3 |
3.225400E-01 |
| Stage2-vs-Stage4 |
5.864800E-01 |
| Stage3-vs-Stage4 |
5.041200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.6266000010049E-08 |
| Normal-vs-AfricanAmerican |
3.39159999973582E-07 |
| Normal-vs-Asian |
3.390900E-04 |
| Caucasian-vs-AfricanAmerican |
1.503030E-01 |
| Caucasian-vs-Asian |
8.223600E-01 |
| AfricanAmerican-vs-Asian |
2.248600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.22340026997847E-10 |
| Normal-vs-Female |
7.67079999519638E-08 |
| Male-vs-Female |
3.335600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.55929996587179E-09 |
| Normal-vs-Age(41-60Yrs) |
6.33360000001915E-07 |
| Normal-vs-Age(61-80Yrs) |
4.24549999600288E-08 |
| Normal-vs-Age(81-100Yrs) |
1.449680E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.941000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.970800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.189800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.460200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.774780E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.780600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.501950E-03 |
| Classical-VS-Follicular |
1.006330E-02 |
| Classical-VS-Other |
4.747200E-01 |
| Classical-VS-Normal |
2.19440000004401E-06 |
| Tall-VS-Follicular |
9.841400E-01 |
| Tall-VS-Other |
7.892200E-01 |
| Tall-VS-Normal |
1.15830012248352E-10 |
| Follicular-VS-Other |
8.840400E-01 |
| Follicular-VS-Normal |
3.99930000227755E-09 |
| Other-VS-Normal |
1.403000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.16670000005881E-07 |
| Normal-vs-N1 |
4.95550001033962E-09 |
| N0-vs-N1 |
1.810400E-01 |
|
|
